Not all psoriasis drugs act the same
For years, many assumed that as inflammation went down, heart risk automatically improved. The logic made sense. Less inflammation should mean healthier blood vessels.
But here’s the twist. The new analysis of 24,575 patients shows that different drug classes have opposite effects on blood fats.
Some drugs improve cholesterol. Others make it worse—even when they’re working well on skin and joints.
This means two patients with identical symptoms could end up with very different heart risks—just based on which drug they take.
The liver’s traffic control system
Cholesterol and triglycerides are fats made and managed by the liver. Think of the liver as a busy shipping hub. It loads up fat packages and sends them into the bloodstream.
Inflammation acts like a traffic jam in this system. It messes up signals. Fat builds up. Arteries get clogged over time.
Some psoriasis drugs clear the jam by reducing inflammation. But others, especially JAK inhibitors, seem to flip a switch that tells the liver to pack more fat into the blood.
It’s like fixing the traffic but then asking the warehouse to ship out twice as many packages. The roads are clear—but now there’s more cargo moving than before.
The study looked at seven types of drugs used in psoriasis and psoriatic arthritis. It combined results from 36 high-quality studies.
The clearest pattern? JAK inhibitors—like tofacitinib and upadacitinib—raise total cholesterol, LDL (the “bad” kind), HDL (the “good” kind), and triglycerides. All go up.
That’s unusual. Most drugs that raise HDL are seen as helpful. But when LDL and triglycerides rise too, the heart risk may go up overall.
On the flip side, TNF inhibitors—like adalimumab and infliximab—do the opposite. They lower total cholesterol, LDL, and triglycerides. They also raise HDL. That’s a pattern linked to lower heart risk.
Two other drugs stand out. IL-17A inhibitors, like secukinumab, raise triglycerides. But IL-23p19 inhibitors, like guselkumab, lower them sharply.
This doesn't mean this treatment is available yet.
If you take a psoriasis drug, this doesn’t mean you should stop it. These medications control serious disease. But it does mean your doctor should check your blood fats regularly.
JAK inhibitors already carry heart risk warnings. This data supports why. Patients on these drugs may need earlier or more frequent cholesterol tests.
For those on TNF or IL-23p19 inhibitors, the news is more reassuring. Their treatment may not add heart risk—and could even help.
Still, no one should choose a drug based on cholesterol alone. Skin and joint control come first. But heart health can’t be ignored.
But there's a catch.
The study shows patterns, not proof. It can’t say whether these cholesterol changes actually lead to more heart attacks or strokes. That’s still unknown.
Most studies tracked blood fats for less than two years. Heart disease builds over decades. We need longer data.
Also, the analysis combined many studies. Each had different designs. Some were trials. Others were real-world reports. That adds uncertainty.
What happens next
Doctors now have strong evidence to guide monitoring. Patients on JAK inhibitors should get routine lipid checks. Those on TNF blockers may need them too—but the risk appears lower.
Drug makers may need to study heart outcomes in future trials. Regulators could update guidelines.
For patients, the message is simple. Talk to your doctor about your heart risk. Ask about your cholesterol. Know which drug you’re on—and how it might affect more than just your skin.
Long-term studies are already in motion. They’ll track whether these blood fat changes translate into real heart events. Until then, vigilance is the best tool.
